会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明申请
    • COMPOSITIONS
    • 组合物
    • WO2011077245A2
    • 2011-06-30
    • PCT/IB2010/003447
    • 2010-12-23
    • FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORRUSSO, VincenzoTRAVERSARI, Catia
    • RUSSO, VincenzoTRAVERSARI, Catia
    • A61K45/06
    • A61K31/4433A61K31/357A61K31/381A61K31/404A61K31/4178A61K31/4196A61K31/496A61K31/575A61K39/395A61K2300/00
    • The invention relates to the discovery that human and murine tumors release LXR ligands (oxysterols) that inhibit CCR7 expression on maturing DC and, therefore, their migration to lymphoid organs. By inhibiting oxysterol synthesis (by Zaragozic Acid, ZA) or by inactivating oxysterols (gene therapy with sulfotransferase SULT2B1 b enzyme) long lasting antigen specific anti-tumor immune response mediated by DC is increased. Surprisingly, we also show that drugs interfering with sterol metabolism (i.e. ZA) in combination with a mAb depleting T regulatory cells potentiate the antitumor effect of the single treatments. This synergic effect is unexpected, providing a new effective combination therapy for the treatment of cancer. The invention also relates to the novel use of LXR ligand inactivators, or of LXR inhibitors/antagonists, for the treatment of cancer. These strategies can also be used in combination with a chemotherapy approach for the treatment of cancer patients.
    • 本发明涉及人和鼠肿瘤释放在成熟DC上抑制CCR7表达并因此其向淋巴器官迁移的LXR配体(氧固醇)的发现。 通过抑制氧固醇合成(通过Zaragozic Acid,ZA)或通过使氧固醇失活(用磺基转移酶SULT2B1b酶进行基因治疗),由DC介导的持久抗原特异性抗肿瘤免疫应答增加。 令人惊讶的是,我们还表明,干扰固醇代谢(即ZA)与消耗血清单克隆抗体T调节细胞的组合的药物增强了单次治疗的抗肿瘤作用。 这种协同效应是意想不到的,为治疗癌症提供了一种新的有效的联合疗法。 本发明还涉及LXR配体灭活剂或LXR抑制剂/拮抗剂在治疗癌症中的新用途。 这些策略也可以与化疗方案结合使用,用于治疗癌症患者。